Mixed-use districts don't reverse the dismal economics of sports venues
1 points, 0 comments on Hacker News
6 headlines
1 points, 0 comments on Hacker News
4 points, 0 comments on Hacker News
The first human patient has received a dose of Life Biosciences’ sight recovery drug.
2 points, 0 comments on Hacker News
The FDA recently approved the cellular rejuvenation therapy ER-100 for human clinical trials. While vision is the first target, it could have applications for a variety of age-related disease.
Cellular reprogramming is the hottest topic in longevity science, with tech titans like Sam Altman investing in it. It's now being tested in humans.